【目的】 探讨桑杏止咳颗粒对燥邪伤肺型咳嗽变异性哮喘（CVA）患者中医证候、炎症反应及通气功能的影响。【方法】 选取 2021年11月至2024年10月衡水市中医医院呼吸科门诊及住院部收治的燥邪伤肺型CVA患者150例，采用随机数字表法将患 者随机分为对照组和桑杏止咳组，每组各75例。对照组给予西医常规治疗，桑杏止咳组在对照组的基础上联合桑杏止咳颗 粒治疗，疗程均为2周。观察2组患者治疗前后中医证候积分、咳嗽症状评分、相关炎症指标及肺通气功能的变化情况，并 评价2组用药的安全性。【结果】（1）中医证候积分方面，治疗后，桑杏止咳组患者的呼吸急促、胸膈满闷、喉中哮鸣、咯痰 不利积分均较治疗前明显下降（P＜0.05），而对照组均较治疗前无明显下降（P＞0.05）；组间比较，桑杏止咳组对各项中医证 候积分的下降幅度均明显优于对照组（P＜0.05）。（2）咳嗽症状评分方面，治疗后，2组患者的日间咳嗽症状评分、夜间咳嗽 症状评分及咳嗽视觉模拟量表（VAS）评分均较治疗前下降（P＜0.05），且桑杏止咳组对各项咳嗽症状评分的下降幅度均明显 优于对照组（P＜0.05）。（3）相关炎症指标方面，治疗后，2组患者的血清肿瘤坏死因子α（TNF-α）、白细胞介素5（IL-5）、巨 噬细胞炎性蛋白 1α（MIP-1α）、嗜酸性粒细胞阳离子蛋白（ECP）水平及外周血嗜酸性粒细胞计数（EOS）值均较治疗前下降 （P＜0.05），且桑杏止咳组对各项炎症指标的下降幅度均明显优于对照组（P＜0.05）。（4）肺通气功能方面，治疗后，2组患者 的用力肺活量（FVC）、第1秒用力呼气容积（FEV1 ）、呼气峰流速（PEF）等肺通气功能指标均较治疗前改善（P＜0.05），且桑杏 止咳组对各项肺通气功能指标的改善幅度均明显优于对照组（P＜0.05）。（5）安全性方面，桑杏止咳组患者的不良反应发生率 为5.33%（4/75），对照组为6.67%（5/75），组间比较，差异无统计学意义（P＞0.05）。【结论】 桑杏止咳颗粒对燥邪伤肺型CVA 患者疗效显著，能有效改善中医证候，减轻咳嗽、咽干等症状；能调节炎症反应，降低炎症因子水平；提升肺通气功能， 缓解气道阻塞，且具有较高的安全性。

Objective To investigate the effects of Sangxing Zhike Granules on traditional Chinese medicine （TCM） syndromes，inflammatory response，and ventilatory function in patients with dryness impairing the lung type of cough variant asthma （CVA）. Methods From November 2021 to October 2024，150 patients diagnosed with CVA of dryness impairing the lung type were recruited from the outpatient and inpatient departments of the Respiratory Medicine Unit at Hengshui Hospital of Traditional Chinese Medicine. These patients were randomly assigned to the control group and the Sangxing Zhike group using a random number table method，with 75 patients in each group. The control group received conventional western medical treatment， while the Sangxing Zhike group received additional Sangxing Zhike Granules based on the conventional treatment. The therapeutic course for both groups was 2 weeks. Changes in TCM syndrome scores， cough symptom scores， relevant inflammatory markers， and pulmonary ventilatory function were assessed before and after treatment. The safety of the treatment was also evaluated. Results （1） In the Sangxing Zhike group，significant reductions were observed in scores for shortness of breath，chest tightness，throat wheezing，and difficult expectoration after treatment （P＜0.05），whereas no significant changes were noted in the control group （P＞0.05）. The intergroup comparisons revealed that the Sangxing Zhike group exhibited significantly greater reductions in all TCM syndrome scores compared to the control group （P＜0.05）.（2） Both groups showed reduced daytime and nighttime cough symptom scores and Visual Analogue Scale （VAS） scores after treatment （P＜0.05）， with the Sangxing Zhike group demonstrating significantly greater improvements than the control group （P＜0.05）.（3） Post-treatment levels of serum tumor necrosis factor- α （TNF- α）， interleukin-5 （IL-5）， macrophage inflammatory protein-1α （MIP-1α）， eosinophil cationic protein （ECP），and peripheral blood eosinophil count （EOS） decreased significantly in both groups （P＜0.05）， with the Sangxing Zhike group showing markedly greater reductions than the control group （P＜0.05）.（4） Both groups exhibited improvements in forced vital capacity （FVC），forced expiratory volume in the first second （FEV1 ），and peak expiratory flow （PEF） after treatment （P＜0.05），with the Sangxing Zhike group demonstrating significantly greater improvements than the control group （P＜0.05）.（5） The incidence of adverse reactions was 5.33% （4/75） in the Sangxing Zhike group and 6.67% （5/75） in the control group，with no statistically significant difference between the two groups （P＞0.05）. Conclusion Sangxing Zhike Granules demonstrate significant efficacy in patients with dryness impairing the lung type of CVA，by effectively improving TCM syndromes， alleviating cough and dry throat symptoms， modulating inflammatory responses， reducing inflammatory cytokine levels， enhancing pulmonary ventilatory function， relieving airway obstruction， and exhibiting high safety.

R256.11

国家自然科学基金资助项目（编号：81704118）；河北省卫生健康委医学科学基金资助项目（编号：20231436）